
SynBioBeta Speaker
Andrei Georgescu
Vivodyne
CEO
Andrei Georgescu, PhD, leads Vivodyne, where lab-grown human tissues are robotically tested at industrial, AI-enabling scale to create human data before clinical trials. The company operates 30,000 square feet of automated biological datacenters across San Francisco and Philadelphia, partnering with the majority of the top-10 pharmaceutical companies to discover and develop better, safer medicines that succeed in clinical trials. He holds a Ph.D. in Bioengineering from the University of Pennsylvania.
Sessions Featuring
Andrei
This Year
•
-
AIxBIO
The Data Reality Check: Human-First Biology for AI Models
Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.
Featuring

Andrei Georgescu
Vivodyne
CEO

Johnny Yu
Tahoe Therapeutics
CSO & Co-founder

Avantika Lal
Genentech
Principal ML Scientist II
Building DNA foundation models that design regulatory sequences.

Daniel Georgiev
Sampling Human
CEO & Co-founder

Krish Ramadurai
AIX Ventures
Partner
TechBio investor backing AI-designed drugs and breakthroughs.
•
-
AIxBIO
The Data Reality Check: Human-First Biology for AI Models
Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.
Featuring

Andrei Georgescu
Vivodyne
CEO

Johnny Yu
Tahoe Therapeutics
CSO & Co-founder

Avantika Lal
Genentech
Principal ML Scientist II
Building DNA foundation models that design regulatory sequences.

Daniel Georgiev
Sampling Human
CEO & Co-founder

Krish Ramadurai
AIX Ventures
Partner
TechBio investor backing AI-designed drugs and breakthroughs.
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon





































